Literature DB >> 12144580

Effects of rabeprazole, 20 mg, or esomeprazole, 20 mg, on 24-h intragastric pH and serum gastrin in healthy subjects.

S Warrington1, K Baisley, M Boyce, B Tejura, A Morocutti, N Miller.   

Abstract

AIM: To compare the antisecretory effects of rabeprazole and esomeprazole in an open, randomized, two-way crossover, clinical pharmacology study.
METHODS: Twenty-four healthy subjects (14 men, 10 women; mean age 26.8 years) received rabeprazole 20 mg or esomeprazole 20 mg daily on days 1-5, with a 14-day 'wash-out'. Intragastric pH was recorded continuously, and serum gastrin measured, on days 0, 1 and 5.
RESULTS: On day 0, mean intragastric pH AUC was significantly higher before the esomeprazole than before the rabeprazole treatment in four of the five time intervals analysed. On days 1 and 5, mean intragastric pH AUC was higher after rabeprazole than esomeprazole during 5-11, 14-24 and 0-24 h after dosing. Mean pH AUC in the first 5 h after dosing on day 5 was higher after esomeprazole than rabeprazole (P=0.012). On day 1, mean per cent times pH > 3 and > 4 were significantly greater after rabeprazole than esomeprazole during 0-14, 14-24 and 0-24 h. On day 5, mean serum gastrin AUC0-4 was higher (P = 0.017) after rabeprazole than esomeprazole (335 vs. 316 pg/mL.h).
CONCLUSION: In this clinical pharmacology study, rabeprazole 20 mg daily was more effective than esomeprazole 20 mg daily in increasing intragastric pH and maintaining pH > 3 and > 4. On day 5, mean pH AUC was higher after esomeprazole than rabeprazole.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12144580     DOI: 10.1046/j.1365-2036.2002.01292.x

Source DB:  PubMed          Journal:  Aliment Pharmacol Ther        ISSN: 0269-2813            Impact factor:   8.171


  17 in total

1.  Study of the pharmacokinetics and intragastric pH of rabeprazole given as successive intravenous infusion to healthy Chinese volunteers.

Authors:  Yongqing Wang; Yaozong Yuan; Ling Meng; Hongwei Fan; Jianming Xu; Hongwen Zhang; Meifeng Wang; Hongyu Yuan; Ning Ou; Haibo Zhang; Yang Chao; Ruihua Shi
Journal:  Eur J Clin Pharmacol       Date:  2010-11-26       Impact factor: 2.953

2.  Daytime intragastric acid control: post hoc analyses of esomeprazole 20 mg and over-the-counter proton-pump inhibitors.

Authors:  Philip Katz; Peter J Kahrilas; David A Johnson; Tore Lind; Kerstin Röhss; Barry Traxler; Vincent Hugo; John Dent
Journal:  Therap Adv Gastroenterol       Date:  2015-11       Impact factor: 4.409

Review 3.  What is potent acid inhibition, and how can it be achieved?

Authors:  Xavier Calvet; Fernando Gomollón
Journal:  Drugs       Date:  2005       Impact factor: 9.546

4.  Rabeprazole test for the diagnosis of gastro-oesophageal reflux disease: results of a study in a primary care setting.

Authors:  Stanislas Bruley des Varannes; Sylvie Sacher-Huvelin; Fabienne Vavasseur; Claude Masliah; Marc Le Rhun; Philippe Aygalenq; Sylvie Bonnot-Marlier; Yves Lequeux; Jean Paul Galmiche
Journal:  World J Gastroenterol       Date:  2006-04-28       Impact factor: 5.742

5.  Adenocarcinoma arising in multiple hyperplastic polyps in a patient with Helicobacter pylori infection and hypergastrinemia during long-term proton pump inhibitor therapy.

Authors:  Hajime Anjiki; Ken-Ichi Mukaisho; Yu Kadomoto; Hisakazu Doi; Kunio Yoshikawa; Takahisa Nakayama; Diem Thi-Ngoc Vo; Takanori Hattori; Hiroyuki Sugihara
Journal:  Clin J Gastroenterol       Date:  2017-02-03

Review 6.  Clinical pharmacology of proton pump inhibitors: what the practising physician needs to know.

Authors:  Malcolm Robinson; John Horn
Journal:  Drugs       Date:  2003       Impact factor: 9.546

Review 7.  Fosamprenavir : clinical pharmacokinetics and drug interactions of the amprenavir prodrug.

Authors:  Mary Beth Wire; Mark J Shelton; Scott Studenberg
Journal:  Clin Pharmacokinet       Date:  2006       Impact factor: 6.447

Review 8.  Relative potency of proton-pump inhibitors-comparison of effects on intragastric pH.

Authors:  Julia Kirchheiner; Silke Glatt; Uwe Fuhr; Ulrich Klotz; Ingolf Meineke; Thomas Seufferlein; Jürgen Brockmöller
Journal:  Eur J Clin Pharmacol       Date:  2008-10-17       Impact factor: 2.953

9.  Esomeprazole 20mg provides more effective intragastric Acid control than maintenance-dose rabeprazole, lansoprazole or pantoprazole in healthy volunteers.

Authors:  Kerstin Röhss; Clive Wilder-Smith; Emma Nauclér; Lennart Jansson
Journal:  Clin Drug Investig       Date:  2004       Impact factor: 2.859

10.  Interchangeable Use of Proton Pump Inhibitors Based on Relative Potency.

Authors:  David Y Graham; Aylin Tansel
Journal:  Clin Gastroenterol Hepatol       Date:  2017-09-28       Impact factor: 11.382

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.